Lexaria Stock Is Trading Higher As DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots

Lexaria Bioscience Corp LEXX has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.

  • The study demonstrated that DehydraTECH enabled colchicine, one of the products tested by Lexaria with known SARS-CoV-2 antiviral properties, benefited from its proprietary formulation and processing, resulting in increased delivery.
  • Colchicine is occasionally recommended and used to treat emergent pericarditis in children when cardiac inflammation develops following administration of mRNA COVID-19 vaccines.
  • It has shown potent effects in mitigating the cytokine storm associated with COVID-19. 
  • Study VIRAL-A20-3 was performed using 20 rats dosed via oral gavage using either DehydraTECH or control colchicine formulations. 
  • The study evaluated peak concentration and total drug delivery into the rodent bloodstream.
  • Colchicine achieved 31.9 ng/mL of peak concentration, compared to 16.7 ng/mL in the control group.
  • Total drug delivery for colchicine reached 104.4 ng/mL versus 38.97 ng/mL for the control arm.
  • Price Action: LEXX shares are up 50.50% at $9.92 during the premarket session on the last check Wednesday.
Loading...
Loading...
LEXX Logo
LEXXLexaria Bioscience Corp
$1.041.96%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
5.52
Growth
Not Available
Quality
Not Available
Value
13.82
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...